UY35687A - Inhibidores de rorc2 y sus métodos de uso - Google Patents
Inhibidores de rorc2 y sus métodos de usoInfo
- Publication number
- UY35687A UY35687A UY35687A UY35687A UY35687A UY 35687 A UY35687 A UY 35687A UY 35687 A UY35687 A UY 35687A UY 35687 A UY35687 A UY 35687A UY 35687 A UY35687 A UY 35687A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- rorc2
- inhibitors
- pharmaceutical compositions
- rorc2 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención proporciona compuestos, composiciones farmacéuticas, métodos para inhibir la actividad de RORy y/o reducir la cantidad de IL-17 en un sujeto, y métodos para tratar los diversos trastornos médicos usando estos compuestos y composiciones farmacéuticas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361861709P | 2013-08-02 | 2013-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35687A true UY35687A (es) | 2015-02-27 |
Family
ID=51570793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY35687A UY35687A (es) | 2013-08-02 | 2014-08-01 | Inhibidores de rorc2 y sus métodos de uso |
Country Status (42)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA40759A (fr) * | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
WO2016120850A1 (en) * | 2015-01-30 | 2016-08-04 | Pfizer Inc. | Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof |
CA2975060C (en) * | 2015-01-30 | 2019-09-03 | Pfizer Inc. | Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof |
CN104672121B (zh) * | 2015-02-16 | 2017-10-24 | 上海华默西医药科技有限公司 | 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法 |
UY36716A (es) * | 2015-06-09 | 2017-01-31 | Abbvie Inc | Moduladores de receptores nucleares |
GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
CN109206401B (zh) * | 2017-06-29 | 2021-03-05 | 南京柯菲平盛辉制药有限公司 | 一类甲基-1H-吲唑类RORγ调节剂及其用途 |
EP3539966A1 (en) * | 2018-03-12 | 2019-09-18 | AbbVie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
MX2021015996A (es) | 2019-07-11 | 2022-06-08 | Escape Bio Inc | Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2). |
CN112745268B (zh) * | 2019-10-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并咪唑衍生物的晶型及制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4742057A (en) * | 1985-12-05 | 1988-05-03 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic thiazole compounds |
HUP9800417A3 (en) * | 1995-03-20 | 2001-04-28 | Lilly Co Eli | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-indoles and 5-substituted-3-(piperidin-4-yl)-1h-indoles, their use as new 5-ht agonists, pharmaceutical compositions containing these compounds |
US5962473A (en) * | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
AU4074897A (en) * | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
DE69819903T2 (de) * | 1997-08-09 | 2004-11-11 | Smithkline Beecham P.L.C., Brentford | Bicyclische verbindungen als liganden der 5-ht1 rezeptoren |
AU4425399A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Novel therapeutic agents that modulate 5-ht receptors |
ES2187300B1 (es) * | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
CA2816753A1 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases |
EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
BR112014029868A2 (pt) * | 2012-05-31 | 2017-06-27 | Phenex Pharmaceuticals Ag | compostos, e, composição farmacêutica |
WO2014026328A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2013171729A2 (en) * | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
-
2014
- 2014-07-24 CU CU2016000015A patent/CU24366B1/es unknown
- 2014-07-24 SG SG11201600200QA patent/SG11201600200QA/en unknown
- 2014-07-24 MA MA38810A patent/MA38810B1/fr unknown
- 2014-07-24 LT LTEP14767126.7T patent/LT3027603T/lt unknown
- 2014-07-24 EA EA201690039A patent/EA029499B9/ru not_active IP Right Cessation
- 2014-07-24 RS RS20181058A patent/RS57618B1/sr unknown
- 2014-07-24 JP JP2016530640A patent/JP6224832B2/ja not_active Expired - Fee Related
- 2014-07-24 PT PT14767126T patent/PT3027603T/pt unknown
- 2014-07-24 AP AP2016009017A patent/AP2016009017A0/xx unknown
- 2014-07-24 WO PCT/IB2014/063383 patent/WO2015015378A2/en active Application Filing
- 2014-07-24 EP EP18182781.7A patent/EP3428160A1/en not_active Withdrawn
- 2014-07-24 CN CN201480043664.4A patent/CN105492434B/zh not_active Expired - Fee Related
- 2014-07-24 CU CU2016000145A patent/CU24398B1/es unknown
- 2014-07-24 MX MX2016001446A patent/MX2016001446A/es unknown
- 2014-07-24 GE GEAP201414046A patent/GEP20186876B/en unknown
- 2014-07-24 TN TN2016000040A patent/TN2016000040A1/fr unknown
- 2014-07-24 EP EP14767126.7A patent/EP3027603B1/en active Active
- 2014-07-24 DK DK14767126.7T patent/DK3027603T3/en active
- 2014-07-24 PE PE2016000213A patent/PE20160801A1/es unknown
- 2014-07-24 BR BR112016001781A patent/BR112016001781A2/pt not_active Application Discontinuation
- 2014-07-24 PL PL14767126T patent/PL3027603T3/pl unknown
- 2014-07-24 UA UAA201600407A patent/UA115908C2/uk unknown
- 2014-07-24 MD MDA20160007A patent/MD20160007A2/ro not_active Application Discontinuation
- 2014-07-24 ES ES14767126.7T patent/ES2685839T3/es active Active
- 2014-07-24 KR KR1020167005139A patent/KR101821903B1/ko active IP Right Grant
- 2014-07-24 CA CA2919783A patent/CA2919783C/en not_active Expired - Fee Related
- 2014-07-24 AU AU2014298017A patent/AU2014298017B2/en not_active Ceased
- 2014-07-24 SI SI201430832T patent/SI3027603T1/sl unknown
- 2014-07-24 HU HUE14767126A patent/HUE039972T2/hu unknown
- 2014-07-30 TW TW106118885A patent/TWI652263B/zh not_active IP Right Cessation
- 2014-07-30 TW TW103126012A patent/TW201516041A/zh unknown
- 2014-07-31 US US14/448,220 patent/US20160046597A1/en not_active Abandoned
- 2014-08-01 AR ARP140102904A patent/AR097199A1/es unknown
- 2014-08-01 UY UY35687A patent/UY35687A/es not_active Application Discontinuation
-
2016
- 2016-01-21 IL IL243728A patent/IL243728B/en not_active IP Right Cessation
- 2016-01-21 PH PH12016500140A patent/PH12016500140A1/en unknown
- 2016-01-25 CR CR20160047A patent/CR20160047A/es unknown
- 2016-01-29 CL CL2016000235A patent/CL2016000235A1/es unknown
- 2016-02-01 NI NI201600021A patent/NI201600021A/es unknown
- 2016-02-02 DO DO2016000039A patent/DOP2016000039A/es unknown
- 2016-02-02 GT GT201600027A patent/GT201600027A/es unknown
- 2016-03-01 EC ECIEPI20168797A patent/ECSP16008797A/es unknown
- 2016-05-10 HK HK16105333.7A patent/HK1219093A1/zh not_active IP Right Cessation
-
2017
- 2017-04-26 US US15/497,862 patent/US20170233371A1/en not_active Abandoned
- 2017-12-07 US US15/834,545 patent/US20180086736A1/en not_active Abandoned
-
2018
- 2018-06-14 US US16/008,419 patent/US20180282304A1/en not_active Abandoned
- 2018-08-08 HR HRP20181291TT patent/HRP20181291T1/hr unknown
- 2018-09-04 CY CY181100917T patent/CY1120751T1/el unknown
-
2019
- 2019-01-30 US US16/261,689 patent/US20190144429A1/en not_active Abandoned
- 2019-10-18 US US16/656,702 patent/US20200039960A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201600021A (es) | Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso | |
UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
DOP2015000274A (es) | Compuestos químicos | |
CR20150462A (es) | Inhibidores de erk y sus usos | |
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
CL2017001046A1 (es) | Inhibidoes del bromodominio | |
CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2017002719A1 (es) | Imidazopirazinonas como inhibidores de pde1 | |
DOP2017000087A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
UY35823A (es) | Profármacos de antagonista de nmda | |
ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
BR112017027721A2 (pt) | formulação de alta concentração | |
BR112015032161A2 (pt) | método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p | |
NZ723269A (en) | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | |
DOP2017000136A (es) | Compuestos para tratar el cáncer | |
CR20140489A (es) | Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211207 |